Atogepant (Qulipta) 3-Year Safety Data Confirms Long-Term Migraine Prevention Efficacy

What Makes Atogepant Different from Other Migraine Preventives?

The calcitonin gene-related peptide (CGRP) pathway has transformed migraine treatment over the past decade. While monoclonal antibodies targeting CGRP or its receptor (erenumab, fremanezumab, galcanezumab, eptinezumab) have shown excellent efficacy, they require monthly or quarterly injections. Atogepant (Qulipta), approved by the FDA in September 2021 for episodic migraine and expanded to chronic migraine in 2023, is a once-daily oral small molecule that blocks the CGRP receptor with comparable efficacy to injectable biologics.

The advantage of oral administration is significant for patient adherence and preference. Research suggests that a majority of migraine patients prefer oral over injectable preventives when given the choice. Atogepant is available in 10 mg, 30 mg, and 60 mg doses, allowing dose titration based on efficacy and tolerability. The 60 mg once-daily dose has shown the greatest migraine day reductions in clinical trials, including the pivotal ADVANCE trial for episodic migraine and the PROGRESS trial for chronic migraine, and is the most commonly prescribed dose for chronic migraine prevention.

What Did the Long-Term Extension Data Show?

Long-term open-label extension studies enrolled patients who had completed the pivotal ADVANCE and PROGRESS trials and elected to continue atogepant 60 mg once daily. Over three years of follow-up, monthly migraine day reductions were sustained without evidence of tolerance or waning efficacy. Both the 50% and 75% responder rates remained stable or improved with continued treatment, suggesting durable benefit with longer treatment duration. These findings are consistent with extension data reported for other CGRP-targeting therapies.

Safety was the primary focus of the extension. The most common adverse events remained constipation, nausea, and fatigue — all of which were mild-to-moderate and generally decreased over time. Hepatic safety monitoring showed no cases of clinically significant liver enzyme elevations, addressing an initial concern with the CGRP receptor antagonist class following the withdrawal of telcagepant due to hepatotoxicity in early development. Importantly, there were no signals of cardiovascular adverse events, rebound headache upon discontinuation, or medication-overuse headache. Weight remained stable throughout the study period.